Full Text View
Tabular View
No Study Results Posted
Related Studies
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
This study has been completed.
Study NCT00461630   Information provided by University of Oxford

First Received on April 17, 2007.   Last Updated on November 19, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cardiovascular Disease
Peripheral Arterial Disease
Diabetes Mellitus
Coronary Heart Disease
Additional conditions recognized in this trial
Cardiovascular Diseases
Coronary Artery Disease
Coronary Disease
Heart Diseases
Myocardial Ischemia
Peripheral Vascular Diseases
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Atherosclerosis
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Vascular Diseases
Interventions listed in this trial
ER niacin/laropiprant
simvastatin
ezetimibe/simvastatin
Additional drug interventions recognized in this trial
Ezetimibe
Niacin
Niacinamide
Nicotinic Acids
More general drug interventions related to this trial
Anticholesteremic Agents
Antimetabolites
Cardiovascular Agents
Enzyme Inhibitors
Growth Substances
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents
Vitamin B Complex
Vitamins
Sponsors listed in this trial
University of Oxford
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services